Changes continue at E-Systems,the parent of PACS developer Advanced Video Products (AVP). TheDallas-based firm has acquired two archival companies and mergedthem into a new subsidiary, EMASS. The new subsidiary will developproducts that will have
Changes continue at E-Systems,the parent of PACS developer Advanced Video Products (AVP). TheDallas-based firm has acquired two archival companies and mergedthem into a new subsidiary, EMASS. The new subsidiary will developproducts that will have applications in medical imaging, accordingto E-Systems.
The acquired companies are Advanced Archival Products (AAP),a Littleton, CO, developer of storage management software forclient-server environments, and Grau Automation, a manufacturerof automated tape libraries, which is located near Stuttgart,Germany. E-Systems also spun off its mass storage operations intothe new subsidiary. E-Systems executive Mitchell Bohn has beenappointed president and COO of EMASS, to be based in Dallas.
E-Systems has been making moves to reposition itself in themedical market. The company let go 13 employees from AVP lastmonth, but at the same time said it remains committed to medicalimaging (SCAN 9/28/94).
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.